Services
Health Technology Assessment
.png){kind=icon}
Strategic and operational support for reimbursement applications, from global evidence planning through to local adaptation.
- Strategic review of value propositions and supporting evidence to align with local HTA requirements.
- End-to-end strategic partnership for HTA submissions, from early planning through to post-submission support and local adaptations.
- Preparation of supporting materials including global value dossiers, evidence summaries, and objection handling documents, translating complex evidence into clear and credible value communication.
- Adaptation of global materials to local HTA standards and country-specific requirements while maintaining consistency across markets.
- Submission support including strategic workshops, mock committee meetings and local technical engagement preparation.
Other services include:
Success Stories
Stay in touch
Subscribe to Symmetron and stay up to date with recent news and announcements.
Oops! Something went wrong while submitting the form.
8 Devonshire Square,
London, EC2M 4PL, UK
Gaining reimbursement for a drug targeting a rare disease
Gaining reimbursement for a drug targeting a rare diseaseEvaluating the cost-effectiveness of a medical device
Evaluating the cost-effectiveness of a medical deviceModelling survival after the clinical trials have ended
Modelling survival after the clinical trials have endedDeveloping a framework for analysing the impact of patient-centred outcomes for achieving reimbursement in the UK
Developing a framework for analysing the impact of patient-centred outcomes for achieving reimbursement in the UKEvaluating the cost-effectiveness of a diagnostic device
Evaluating the cost-effectiveness of a diagnostic deviceOvercoming limited evidence to gain reimbursement for a blockbuster oncology drug
Overcoming limited evidence to gain reimbursement for a blockbuster oncology drugOvercoming the short-term bias in clinical evidence to compare long-term efficacy of psoriasis treatments
Overcoming the short-term bias in clinical evidence to compare long-term efficacy of psoriasis treatmentsValidating comparisons of disease treatments in the absence of head-to-head trials
Validating comparisons of disease treatments in the absence of head-to-head trials